Evidence map›Paper›PMID 29138220›Full record

ArticleBlood2017

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

Kathy S Wang, Haesook T Kim, Sarah Nikiforow, Alexander T Heubeck, Vincent T Ho, John Koreth, Edwin P Alyea, Philippe Armand, Bruce R Blazar, Robert J Soiffer and 3 more

Abstract read
In one paragraph

Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Human OX40L-CAR-TScience translational medicine · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kathy S WangDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Haesook T KimDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Sarah NikiforowDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Alexander T HeubeckDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Vincent T HoDivision of Hematologic Malignancies, Department of Medical Oncology, and.
John KorethDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Edwin P AlyeaDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Philippe ArmandDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Bruce R BlazarDivision of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN.
Robert J SoifferDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Joseph H AntinDivision of Hematologic Malignancies, Department of Medical Oncology, and.
Corey S CutlerDivision of Hematologic Malignancies, Department of Medical Oncology, and.ORCID 0000-0001-8728-4314
Jerome RitzDivision of Hematologic Malignancies, Department of Medical Oncology, and.ORCID 0000-0001-5526-4669

Funding

Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME · 2009 to 2019
$17.5M
Manipulation of Immune Responsiveness after Hematopoietic Cell TransplantationR01CA183559 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$3.7M
Reconstitution of Regulatory T Cells After Stem Cell TransplantationR01CA183560 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME, SOIFFER, ROBERT JON · 2013 to 2017
$2.5M
NCI NIH HHS P01 CA142106NCI NIH HHS R01 CA183559NCI NIH HHS R01 CA183560NIAID NIH HHS P01 AI056299
6 · The paper itself

Abstract

Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex immune response resulting in chronic damage to multiple tissues. Previous studies indicated that donor B cells and the antibodies they produce play an important role in the development of cGVHD. To understand the pathogenic role of antibodies in cGVHD, we focused our studies on posttransplant production of immunoglobulin G antibodies targeting cell surface antigens expressed in multiple cGVHD affected tissues, due to their potential functional impact on living cells in vivo. Using plate-bound cell membrane proteins as targets, we detected a significantly higher level of antibodies reactive with these membrane antigens in patients who developed cGVHD, compared with those who did not and healthy donors. Plasma-reactive antibody levels increased significantly prior to the clinical diagnosis of cGVHD and were reduced following cGVHD therapies including prednisone, interleukin-2, or extracorporeal photophoresis. Using cell-based immunoprecipitation with plasma from cGVHD patients and mass spectrometry, we identified 43 membrane proteins targeted by these antibodies. The presence of antibodies in cGVHD patients' plasma that specifically target 6 of these proteins was validated. Antibodies reactive with these 6 antigens were more frequently detected in patients with cGVHD compared with patients without cGVHD and healthy donors. These results indicate that antibodies that target membrane antigens of living cells frequently develop in cGVHD patients and further support a role for B cells and antibodies in the development of cGVHD.

Indexed as

AdultAgedAntibodiesAntibody FormationAntigens, SurfaceChronic DiseaseFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunoprecipitationMaleMass SpectrometryMiddle AgedTransplantation, HomologousYoung AdultAntibodiesAntigens, Surface

Identifiers

PMID29138220
PMCPMC5746671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.